Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

Patheon Sees Improvement For Contract Drug Makers

By Pharmaceutical Processing | June 11, 2010

TORONTO — Patheon Inc. says there’s strong evidence that the drug manufacturing industry is showing signs of improvement, the Toronto-based company said Friday as it posted a US$10.9-million profit for its latest quarter.

Revenue was US$175.4 million, about five per cent higher than the year-earlier comparable figure, while net income amounted to 8.4 cents per share.

A year earlier, Patheon had a loss of US$3.2 million or 3.5 cents per share with US$167.4 million of revenue.

“We are seeing strong evidence of an improving pharmaceutical contract services business climate for Patheon,” said Wes Wheeler, Patheon’s chief executive officer and president.

On Thursday, Patheon announced it had signed an expanded contract manufacturing agreement with U.S. pharma giant Merck & Co. Inc.

Financial terms or manufacturing specifics of the deal weren’t revealed.

Patheon, a Canadian-American company now based in Research Triangle Park, N.C., said it will produce drugs and provide service from eight of its global manufacturing plants.

The former Toronto-based company employs more than 4,500 people and has 11 manufacturing plans and eight development centres in Canada, the United States and Europe.

New Jersey-based Merck, which employs 100,000 people, develops and sells medicines, vaccines, biologic therapies, and consumer and animal products around the world.

 

Related Articles Read More >

Great Point Partners logo.
Great Point Partners acquires majority stake in Eutecma to fuel sustainable cold chain growth
Driving success in fast-paced high-tech pharma construction projects
This is a photo of the Fujifilm Diosynth Biotechnologies plant under construction in Holly Springs, North Carolina.
Fujifilm, Regeneron ink $3B U.S. manufacturing agreement
This is the logo of Johnson & Johnson.
J&J breaks ground on $2B manufacturing facility in North Carolina
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE